- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations5/19/15 10:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Tuesday, June 2, 2015 at 4:30 p.m. EDT. The purpose of the call is to provide an update on Pfizer’s oncology business and to review Pfizer’s ASCO data presentations. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analyst and Investor Call to Reviewmore...
Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira5/14/15 12:27 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously announced proposed acquisition of Hospira. The request for information from the FTC, often referred to as a “second request,” was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”). Pfizermore...
5/14/15 8:07 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that Director Marc Tessier-Lavigne, Ph.D. has decided to step down from its Board of Directors on May 14, 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr. Tessier-Lavigne is a co-founder of Denali, and he will serve as the chairman of the company. “We’d like to thank Dr. Tessier-Lavigne for hismore...
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody5/13/15 5:01 pm EDT
DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer today announced multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab* at the 2015 American Society of Clinical Oncology (ASCO) annual meeting. Avelumab (also known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptivemore...
- Early data demonstrates advances in the understanding of investigational immuno-oncology therapy avelumab across multiple tumor types
- First presentations at a major global medical meeting since the formation of the alliance between Merck KGaA, Darmstadt, Germany and Pfizer
5/11/15 4:30 pm EDT
Option May Be Exercised Based on Phase II Trial Results for Recombinant Human Alkaline PhosphataseBUNNIK, The Netherlands & NEW YORK--(BUSINESS WIRE)--AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and Pfizer Inc. (NYSE:PFE) announced today that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatmentmore...
5/6/15 12:48 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today two strategic appointments in the leadership of the Worldwide Research and Development organization effective immediately. Michael D. Ehlers, M.D., Ph.D., has been selected as Group Senior Vice President and Head of BioTherapeutics Research & Development and Site Head for Pfizer’s Cambridge and Boston, Massachusetts locations. Dr. Ehlers will report directly to Mikael Dolsten, M.D., Ph.D., President of Worldwidemore...
4/28/15 7:00 am EDT
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for first-quarter 2015. The company manages its commercial operations through two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment (GIP)(3) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC)(3). The Established Productsmore...
- First-Quarter 2015 Reported Revenues(1) of $10.9 Billion
- First-Quarter 2015 Adjusted Diluted EPS(2) of $0.51, Reported Diluted EPS(1) of $0.38; Both Adjusted Diluted EPS(2) and Reported Diluted EPS(1) Include a $0.03 Negative Impact Associated with an Upfront Payment to OPKO Health, Inc. (OPKO)
- Repurchased $6.0 Billion of Common Stock in First-Quarter 2015, Including a $5.0 Billion Accelerated Share Repurchase Agreement Executed in February
- Updated Certain Components of 2015 Financial Guidance Solely to Reflect the Negative Impact of Recent Changes in Foreign Exchange Rates
4/23/15 2:07 pm EDT
Declares 28-Cent Second-Quarter 2015 DividendNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 28-cent second-quarter 2015 dividend on the company’s common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015. The second-quarter 2015 cash dividend will be the 306th consecutive quarterly dividend paid by Pfizer. “In 2014, we returned nearly $12 billion to shareholders through dividends and share repurchases,” said Ian Read, chairmanmore...
Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer4/21/15 10:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that XALKORI® (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Occurring in approximately one percent of NSCLC cases1, ROS1-positive NSCLC represents a particular molecular subgroup of NSCLC.2 XALKORI currently is approved in the U.S. for the treatment of patientsmore...
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia4/21/15 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) compared to that achieved with standard of care chemotherapy. The Phase 3 study has two primary endpoints, complete hematologic remission rate andmore...